IVRO (Invitro International) YoY EBITDA Growth: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Invitro International YoY EBITDA Growth?

Invitro International IVRO +1.33% YoY EBITDA Growth is 0.00% as of Mar. 2026. The stock has 1 warning sign investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Invitro International's YoY EBITDA Growth for the quarter that ended in Mar. 2026 was 0.00%.

Invitro International's EBITDA per Share for the three months ended in Mar. 2026 was $0.00.

Invitro International YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Invitro International's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invitro International YoY EBITDA Growth Chart

Invitro International Annual Data
Trend Feb90 Feb91 Sep92 Sep93 Sep94 Sep95 Sep96 Sep24 Sep25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only 27.54 38.01 38.26 102.11 33.33

Invitro International Quarterly Data
Sep94 Dec94 Mar95 Jun95 Sep95 Dec95 Mar96 Jun96 Sep96 Dec96 Mar97 Jun97 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 100.00 0.00 0.00 -100.00 0.00

Invitro International YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Invitro International's YoY EBITDA Growth for the fiscal year that ended in Sep. 2025 is calculated as:

YoY EBITDA Growth (A: Sep. 2025 )
=(EBITDA per Share (A: Sep. 2025 )-EBITDA per Share (A: Sep. 2024 ))/ | EBITDA per Share (A: Sep. 2024 ) |
=(0.004-0.003)/ | 0.003 |
=33.33 %

Invitro International's YoY EBITDA Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (Q: Mar. 2026 )
=(EBITDA per Share (Q: Mar. 2026 )-EBITDA per Share (Q: Mar. 2025 )) / | EBITDA per Share (Q: Mar. 2025 )) |
=(0.001-0)/ | 0 |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 0.00% mean?
Invitro International (IVRO) has a YoY EBITDA Growth of 0.00% as of Mar. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Invitro International and its competitors.
Is Invitro International's YoY EBITDA Growth too high?
Invitro International's current YoY EBITDA Growth is 0.00%.
How does Invitro International's YoY EBITDA Growth compare to IDTA and PRPH?
Invitro International's YoY EBITDA Growth of 0.00% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Diagnostics & Research company?
A good YoY EBITDA Growth depends on the Medical Diagnostics & Research industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Invitro International and its competitors. Invitro International's current YoY EBITDA Growth is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invitro International stock overvalued right now?
Based on GuruFocus' analysis, Invitro International (IVRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.07 — trading 35.8% above its estimated fair value. The current YoY EBITDA Growth is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Invitro International (IVRO), the current YoY EBITDA Growth is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invitro International Business Description

Address 330 East Orangethorpe Avenue, Suite D, Placentia, CA, USA, 92870
Invitro International is a provider of non-animal testing methods. The company develops and commercializes test kits and laboratory services. Its testing technologies are designed to produce data regarding corrosivity, or ocular/dermal irritation, which correlate with animal and human test results. Its products and services include Irritection, Corrositex, and Lab Services. The company provides its products to various industries such as cosmetics, personal care, household products, textiles, pharmaceuticals, chemicals, and hazardous waste transportation. The majority of its revenue is generated from the United States and it also exports to other countries.